Stryker (SYK) Competitors

In the previous week, Boston Scientific had 25 more articles in the media than Stryker. MarketBeat recorded 56 mentions for Boston Scientific and 31 mentions for Stryker. Stryker's average media sentiment score of 0.96 beat Boston Scientific's score of 0.63 indicating that Stryker is being referred to more favorably in the media.

Stryker currently has a consensus target price of $395.48, indicating a potential upside of 29.35%. Boston Scientific has a consensus target price of $87.46, indicating a potential upside of 81.00%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Stryker has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Boston Scientific has a net margin of 17.29% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Boston Scientific's return on equity.

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 4.6% of Stryker shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Stryker has higher earnings, but lower revenue than Cardinal Health. Cardinal Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

In the previous week, Stryker had 27 more articles in the media than Cardinal Health. MarketBeat recorded 31 mentions for Stryker and 4 mentions for Cardinal Health. Stryker's average media sentiment score of 0.96 beat Cardinal Health's score of 0.89 indicating that Stryker is being referred to more favorably in the media.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.2%. Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 1.0%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 32 consecutive years and Cardinal Health has increased its dividend for 29 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

77.1% of Stryker shares are held by institutional investors. Comparatively, 87.2% of Cardinal Health shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.1% of Cardinal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Stryker has a net margin of 13.20% compared to Cardinal Health's net margin of 0.62%. Stryker's return on equity of 23.42% beat Cardinal Health's return on equity.

Stryker presently has a consensus price target of $395.48, indicating a potential upside of 29.35%. Cardinal Health has a consensus price target of $241.80, indicating a potential upside of 23.01%. Given Stryker's higher possible upside, equities analysts plainly believe Stryker is more favorable than Cardinal Health.

Stryker currently has a consensus target price of $395.48, suggesting a potential upside of 29.35%. Cencora has a consensus target price of $380.25, suggesting a potential upside of 41.25%. Given Cencora's stronger consensus rating and higher probable upside, analysts plainly believe Cencora is more favorable than Stryker.

77.1% of Stryker shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Comparatively, 0.4% of Cencora shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Cencora has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Stryker has higher earnings, but lower revenue than Cencora. Cencora is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker has a net margin of 13.20% compared to Cencora's net margin of 0.78%. Cencora's return on equity of 135.20% beat Stryker's return on equity.

Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.2%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.9%. Stryker pays out 40.7% of its earnings in the form of a dividend. Cencora pays out 18.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 32 consecutive years and Cencora has raised its dividend for 15 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Stryker had 19 more articles in the media than Cencora. MarketBeat recorded 31 mentions for Stryker and 12 mentions for Cencora. Stryker's average media sentiment score of 0.96 beat Cencora's score of 0.52 indicating that Stryker is being referred to more favorably in the media.

Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, DaVita has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

77.1% of Stryker shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Comparatively, 1.5% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Stryker has a net margin of 13.20% compared to DaVita's net margin of 5.65%. Stryker's return on equity of 23.42% beat DaVita's return on equity.

Stryker has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Stryker presently has a consensus price target of $395.48, indicating a potential upside of 29.35%. DaVita has a consensus price target of $199.17, indicating a potential upside of 2.58%. Given Stryker's stronger consensus rating and higher probable upside, analysts plainly believe Stryker is more favorable than DaVita.

In the previous week, Stryker had 27 more articles in the media than DaVita. MarketBeat recorded 31 mentions for Stryker and 4 mentions for DaVita. Stryker's average media sentiment score of 0.96 beat DaVita's score of 0.92 indicating that Stryker is being referred to more favorably in the media.